Biotechnology Law Report

Papers
(The median citation count of Biotechnology Law Report is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Selected Developments in Biotechnology Law and the Biotechnology Industry3
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC3
Bracco Diagnostics Inc. v. Maia Pharm., Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1387, 2020 WL 7393233 (Non-precedential)3
The EPO Guidelines They Are a-Changin’3
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China2
Immunex Corp. v. Sanofi-Aventis U.S. LLC United States Court of Appeals of the Federal Circuit, 202977 F.3d 12122
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?2
How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.1
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich1
Pfizer Inc. v. Sanofi Pasteur Inc1
Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd1
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13551
The Localization of Drug Patent Linkage System in China: Where Should It Go?1
ChromaDex, Inc. v. Elysium Health, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 12801
The U.S. Patent and Trademark Office’s Response to Recent Developments in Artificial Intelligence1
Pac. Biosciences of California, Inc. v. Oxford Nanopore Techs., Inc. United States Court of Appeals of the Federal Circuit, 2021 996 F.3d 1341
In re Bd. of Trustees of Leland Stanford Junior Univ. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1012, 2021 WL 9227271
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13301
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Research on Intellectual Property Right Protection of Genetic Resources in China Under Benefit-Sharing1
Univ. of S. Fla. Bd. of Trustees v. United States and the Federal Government’s Nonexclusive License under the Bayh-Dole Act1
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies1
Novartis Pharms. Corp. v. Accord Healthcare, Inc.1
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control1
Par Pharm., Inc. v. Eagle Pharms., Inc.1
The Redemption of Drug Patent Linkage System: The Dilemma and Improvement in the Qualification System of Market Exclusivity Period for China’s First Generic Drug1
Legal Governance of Human Gene Editing Technology: From Single Governance to Multiple Governance1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
A Review of Judicial Opinions Interpreting the Novelty Provisions of the America Invents Act1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines1
Cornell Rsch. Found., Inc. v. Vidal1
Univ. of Massachusetts v. L'Oreal S.A.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13711
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Pac. Biosciences of California, Inc. v. Pers. Genomics Taiwan, Inc1
ModernaTx, Inc. v. Arbutus Biopharma Corp.1
The Drawing-Up of Laws on Research Involving Human Embryos in Australia: Lack of an Islamic Voice1
An Innovation Principle in Gene Technology Law?1
Taiwan's Efforts to Recreate Remdesivir1
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II1
Legal and Ethical Challenges in the Construction of China's Biobanks1
Regulatory Landscape for Generic Drugs in India: Assessing Quality, Safety, and Efficacy Standards1
Amarin Pharma, Inc. v. Hikma Pharms. USA, Inc.1
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc1
Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Biotechnology Law Report1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.United States Court of Appeals of the Federal Circuit, 20217 F.4th 13201
Japanese CRISPR Patent and Biotech Developments in the Early Reiwa Era1
Research on the Latest Progress of “Mechanism for Early Resolution of Patent Disputes” for Biological Products in China1
Supplementary Protection Certificates in Europe: Clarity at Last?1
Review of the UK's R&D Tax Reliefs—A Good News Story for the UK's Life Sciences Sector?1
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.1
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?1
A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point1
Innovate, Evaluate, Legislate: U.S. Senators Forge a Path to Assess Artificial Intelligence’s Biosecurity Quandary0
Legislative Moves on Biosecurity in China0
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
The Fate of FTC v. Actavis, Inc. in the Biosimilar Context—Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Minerva Surgical, Inc. v. Hologic, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 13710
Regulation of Clinical Trials and Pandemic Research: Upholding Ethical Standards During a COVID-19 Crisis0
Par Pharm., Inc. v. Hospira, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1273, 2020 WL 6846347 (Non-precedential)0
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings0
In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific “Fringe”0
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10800
Univ. of S. Fla. Bd. of Trustees v. United States0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC United States Court of Appeals of the Federal Circuit, 2023 No. 2023-1186, 2023 WL 21986400
C R Bard Inc. v. AngioDynamics, Inc. United States Court of Appeals of the Federal Circuit, 2020 979 F.3d 13720
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption0
AstraZeneca AB v. Mylan Pharms. Inc.0
Unproven Stem Cell Industry in the U.S.: Regulatory Challenges and Enforcement Issues0
Actelion Pharms. LTD v. Mylan Pharms. Inc.0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
A Crisis on Patenting of “Ready-to-Use” Oral Liquid Formulations: Azurity Pharms., Inc. v. Alkem Lab’ys Ltd0
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources0
Salix Pharms., Ltd. v. Norwich Pharms. Inc.0
Arbutus Biopharma Corp. v. ModernaTX, Inc. United States Court of Appeals of the Federal Circuit, 2023 65 F.4th 6560
Horizon Pharma, Inc. v. Dr. Reddy's Labs. Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-1607, 2021 WL 48428 (Non-precedential)0
Medytox, Inc. v. Galderma S.A.0
Celanese Int’l Corp. v. Int’l Trade Comm’n0
Purdue Pharma L.P. v. Collegium Pharm., Inc0
Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC0
Pharmaceutical Patent Term Compensation System in China—Centered on Article 42(3) of the Amendment to the Patent Law of the People's Republic of China0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
A Pharmaceutical Formulation as a Claim Term Cannot “Target” a Plasma Concentration-Time Profile Under 35 U.S.C. § 112: A Lesson from Horizon Pharma, Inc. v. Dr. Reddy's Laboratories Inc.0
China Releases Document on Ethics Review of Life Sciences: Comments and Compliance Guidelines0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Regulation of Biomedical Research: Global and Indian Perspective0
The Legal Protection of Gene Private Rights0
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods0
H. Lundbeck A/S v. Lupin Ltd.0
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine0
A 12th Year 101 Update—Diagnostic and DNA Claims Are Patent Eligible, but Pre-Mayo Patents May Continue to Fall0
Ferring B.V. v. Allergan, Inc. United States Court of Appeals of the Federal Circuit, 2020 980 F.3d 8410
Eli Lilly & Co. v. Apotex, Inc. United States Court of Appeals of the Federal Circuit, 2020 No. 2020-1328, 2020 WL 7490251 (Non-precedential)0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
The U.S. Patent and Trademark Office Proposes New Rules Targeting Continuation Practice and Terminal Disclaimers0
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR0
Takeda Pharm. Co. Ltd. v. Torrent Pharm. Ltd. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1552, 2021 WL 560763 (nonprecedential)0
Challenges in Patenting Human Stem Cell Inventions: A Comparative Perspective in USA, Europe, and India—Is India Lagging?0
Gilead Scis., Inc. v. United States0
Recent Developments in FDA Regulatory Exclusivities0
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1470
Astellas Pharma, Inc. v. Sandoz Inc. USA, Inc.0
Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr0
Recent Developments in the Listing of Patents in FDA's Orange Book0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws0
Genentech, Inc. v. Sandoz, Inc.0
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.0
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine0
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9640
The Evolving Grace Period for U.S. Patent Applicants0
Galderma Lab’ys, L.P. v. Lupin Inc0
Amgen Inc. v. Sandoz Inc. United States Court of Appeals of the Federal Circuit, 2023 No. 2022-1147, 2023 WL 29941660
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I0
Allergan USA, Inc. v. MSN Lab’ys Priv. Ltd0
In Minerva v. Hologic, the U.S. Supreme Court Reins in the Equitable Doctrine of Assignor Estoppel0
In re Couvaras0
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.0
Introduction on Biosafety Law of the People's Republic of China and Linkage Thereof with International and Domestic Regulations0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Sanho Corp. v. Kaijet Tech. Int’l Ltd., Inc0
A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition0
Government Involvement in Pharmaceutical Development Can Come Back to Haunt a Drug Company0
Vectura Ltd. v. Glaxosmithkline LLC. United States Court of Appeals of the Federal Circuit, 2020 981 F.3d 10300
Janssen Ortho, LLC v. United States0
Minerva Surgical, Inc. v. Hologic, Inc.0
Natera, Inc. v. NeoGenomics Lab’ys, Inc0
UCB, Inc. v. Actavis Lab'ys UT, Inc.0
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-190
Branded Drug Companies Are Successfully Asserting the Doctrine of Equivalents in Hatch-Waxman Litigation0
United Therapeutics Corp. v. Liquidia Techs., Inc.0
A Review of Patent Regimes on Health Biotechnology Innovation in India0
Bio-Rad Lab'ys, Inc. v. Int'l Trade Comm'n0
Valeant Pharm. N. Am. LLC v. Mylan Pharm. Inc. United States Court of Appeals of the Federal Circuit, 2020 978 F.3d 13740
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)0
Navigating Cross-Border Challenges In Biobanking: Analysing Eu Legislation, ECJ Case Law, and the Role of Private International Law0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Hologic, Inc. v. Minerva Surgical, Inc.0
GlaxoSmithKline II and Other Recent Developments in Induced and Contributory Patent Infringement0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
AI (Re)Defining Pharmaceutical Exclusivities0
Patentability Analysis of “Intelligent” Disease Diagnosis Methods in China in the Era of Smart Health Care0
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Biotechnology Law Report0
The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)0
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law0
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law0
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy0
Ethical Boundary of the Development of Human Gene Editing Technology0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
The Compulsory Licensing for Exploiting Patented COVID-19 Pharmaceutical Treatment: Legal Approaches of Some Arab Countries0
Legal Perspective of Genetically Modified Crops and Drowsy Stance of International Actors0
0.061380863189697